We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORTX
176
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$659K 0.05%
15,000
-10,000
-40% -$557K
IRD
177
Opus Genetics
IRD
$287M
$632K 0.05%
119,551
– –
IMVT icon
178
PUT
Immunovant
IMVT
$7.93B
$610K 0.05%
57,700
-185,100
-76% -$2.58M
STOK icon
179
PUT
Stoke Therapeutics
STOK
$1.84B
$606K 0.05%
18,000
-84,000
-82% -$2.97M
BGMS
180
Bio Green Med Solution Inc
BGMS
$4.86M
$593K 0.05%
28
-55
-66% -$1.36M
AGEN
181
Agenus
AGEN
$276M
$570K 0.05%
5,291
-29,296
-85% -$2.2M
NVAX icon
182
Novavax
NVAX
$1.21B
$559K 0.05%
2,636
– –
ANAB icon
183
AnaptysBio
ANAB
$1.54B
$558K 0.05%
21,553
+12,000
+126% +$288K
DCTH icon
184
Delcath Systems
DCTH
$400M
$555K 0.04%
43,915
– –
CLDX icon
185
PUT
Celldex Therapeutics
CLDX
$2.94B
$535K 0.04%
+16,000
New +$439K
LRMR icon
186
Larimar Therapeutics
LRMR
$377M
$520K 0.04%
52,968
-372,416
-88% -$4.21M
PBYI icon
187
Puma Biotechnology
PBYI
$398M
$504K 0.04%
54,901
– –
OTIC
188
DELISTED
Otonomy, Inc.
OTIC
$472K 0.04%
+211,471
New +$489K
GNCA
189
DELISTED
Genocea Biosciences, Inc.
GNCA
$468K 0.04%
200,000
+121,233
+154% +$292K
ALEC icon
190
CALL
Alector
ALEC
$169M
$465K 0.04%
+22,300
New +$420K
ALEC icon
191
PUT
Alector
ALEC
$169M
$465K 0.04%
+22,300
New +$420K
FLNA
192
Filana Therapeutics
FLNA
$42M
$458K 0.04%
+5,362
New +$287K
CHMA
193
DELISTED
Chiasma, Inc. Common Stock
CHMA
$428K 0.03%
90,437
-519,862
-85% -$1.96M
TVRD
194
Tvardi Therapeutics
TVRD
$20.1M
$418K 0.03%
815
-14,700
-95% -$9.32M
VCEL icon
195
CALL
Vericel Corp
VCEL
$2.38B
$416K 0.03%
7,900
– –
MREO
196
Mereo BioPharma
MREO
$48.9M
$346K 0.03%
944,308
-202,000
-18% -$678K
APTO
197
DELISTED
Aptose Biosciences, Inc.
APTO
$346K 0.03%
231
– –
COGT icon
198
Cogent Biosciences
COGT
$6.76B
$338K 0.03%
41,762
– –
FATE icon
199
Fate Therapeutics
FATE
$275M
$313K 0.03%
3,600
– –
RCOR
200
DELISTED
Renovacor, Inc.
RCOR
$300K 0.02%
30,000
– –
6 7
8
9 10

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.